Please login to the form below

Not currently logged in
Email:
Password:

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.

Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.

Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.

Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.

“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”

Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.

Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.

4th February 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics